Aimmune Therapeutics, Inc.
DelistedCIK 1631650fmd_02QQXCR8X6EPQ1E3NSM4TK9VYDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2020, 27 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|---|---|---|
| Research and development | 3 | 8 | 20 | 55 | 89 | 133 | 124 |
| Total operating expenses | 5 | 11 | 36 | 82 | 133 | 215 | 250 |
| Operating income | (5) | (11) | (36) | (82) | (133) | (215) | (250) |
| Interest expense | 0 | – | 0 | – | 0 | 0 | 5 |
| Interest and investment income | – | – | – | – | 2 | 5 | 6 |
| Other non-operating income (expense) | 0 | 0 | 0 | 1 | (0) | (0) | 1 |
| Income before taxes | (5) | (11) | (36) | (81) | (131) | (211) | (248) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 1 |
| Net income from continuing operations | – | (11) | (36) | (81) | (131) | (211) | (248) |
| Net income | (5) | (11) | (36) | (81) | (131) | (211) | (248) |